Learning from epidemiological, clinical, and immunological studies on Mycobacterium africanum for improving current understanding of host-pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies, and vaccines for tuberculosis

Zumla, Alimuddin, Otchere, Isaac Darko, Mensah, Gloria Ivy, Asante-Poku, Adwoa, Gehre, Florian, Maeurer, Markus, Bates, Matthew, Mwaba, Peter, Ntoumi, Francine and Yeboah-Manu, Dorothy (2017) Learning from epidemiological, clinical, and immunological studies on Mycobacterium africanum for improving current understanding of host-pathogen interactions, and for the development and evaluation of diagnostics, host-directed therapies, and vaccines for tuberculosis. International Journal of Infectious Diseases, 56 (SI). pp. 126-129. ISSN 1201-9712

Full content URL: https://doi.org/10.1016/j.ijid.2016.12.003

Documents
Zumla Africanum IJID 2017.pdf
[img]
[Download]
[img]
Preview
PDF
Zumla Africanum IJID 2017.pdf - Whole Document
Available under License Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.

275kB
Item Type:Article
Item Status:Live Archive

Abstract

Mycobacterium africanum comprises two phylogenetic lineages within the Mycobacterium tuberculosis complex (MTBC). M. africanum was first described and isolated in 1968 from the sputum of a Senegalese patient with pulmonary tuberculosis (TB) and it has been identified increasingly as an important cause of human TB, particularly prevalent in West Africa. The restricted geographical distribution of M. africanum, in contrast to the widespread global distribution of other species of MTBC, requires explanation. Available data indicate that M. africanum may also have important differences in transmission, pathogenesis, and host-pathogen interactions, which could affect the evaluation of new TB intervention tools (diagnostics and vaccines)-those currently in use and those under development. The unequal geographical distribution and spread of MTBC species means that individual research findings from one country or region cannot be generalized across the continent. Thus, generalizing data from previous and ongoing research studies on MTBC may be inaccurate and inappropriate. A major rethink is required regarding the design and structure of future clinical trials of new interventions. The West, Central, East, and Southern African EDCTP Networks of Excellence provide opportunities to take forward these pan-Africa studies. More investments intomolecular, epidemiological, clinical, diagnostic, and immunological studies across the African continent are required to enable further understanding of host-M. africanum interactions, leading to the development of more specific diagnostics, biomarkers, host-directed therapies, and vaccines for TB. (C) 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license.

Keywords:T, Mycobacterium africanum, Mycobacterium tuberculosis complex, Host, Diagnostics, Vaccines, extbackslashAfrica, EDCTP}
Subjects:C Biological Sciences > C520 Medical and Veterinary Microbiology
A Medicine and Dentistry > A300 Clinical Medicine
Divisions:College of Science > School of Life Sciences
ID Code:28347
Deposited On:06 Sep 2017 14:13

Repository Staff Only: item control page